| http://dbpedia.org/ontology/abstract
|
Phio Pharmaceuticals Inc. is a US biotechn … Phio Pharmaceuticals Inc. is a US biotechnology company focused on the field of siRNA. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phios Pharmaceuticals in 2018. The company is using its siRNA platform to develop a pipeline of dermatology and ophthalmology therapeutics. The company has developed self-delivering RNAi compounds for the treatment of dermal and retinal scarring and is also working on a proprietary topical formulation of diphenylcyclopropenone for the treatment of warts, alopecia areata and cutaneous metastases of melanoma.eata and cutaneous metastases of melanoma.
|
| http://dbpedia.org/ontology/foundingYear
|
2011
|
| http://dbpedia.org/ontology/industry
|
http://dbpedia.org/resource/Biotechnology +
|
| http://dbpedia.org/ontology/keyPerson
|
http://dbpedia.org/resource/Chairman +
, http://dbpedia.org/resource/Chief_Executive_Officer +
|
| http://dbpedia.org/ontology/location
|
http://dbpedia.org/resource/Marlborough%2C_Massachusetts +
|
| http://dbpedia.org/ontology/type
|
http://dbpedia.org/resource/Public_company +
|
| http://dbpedia.org/ontology/wikiPageID
|
35289132
|
| http://dbpedia.org/ontology/wikiPageLength
|
9299
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1082536316
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Small_interfering_RNA +
, http://dbpedia.org/resource/Orphan_Drug +
, http://dbpedia.org/resource/Ophthalmology +
, http://dbpedia.org/resource/Chairman +
, http://dbpedia.org/resource/Warts +
, http://dbpedia.org/resource/CTGF +
, http://dbpedia.org/resource/Medicinal_chemistry +
, http://dbpedia.org/resource/OTC_Markets_Group +
, http://dbpedia.org/resource/Category:Companies_listed_on_the_Nasdaq +
, http://dbpedia.org/resource/Over-the-counter_%28finance%29 +
, http://dbpedia.org/resource/Craig_Mello +
, http://dbpedia.org/resource/Fibrosis +
, http://dbpedia.org/resource/Alopecia_areata +
, http://dbpedia.org/resource/Liposome +
, http://dbpedia.org/resource/Johnson_&_Johnson +
, http://dbpedia.org/resource/Diphenylcyclopropenone +
, http://dbpedia.org/resource/Public_company +
, http://dbpedia.org/resource/Galena_Biopharma +
, http://dbpedia.org/resource/CytRx +
, http://dbpedia.org/resource/Los_Angeles +
, http://dbpedia.org/resource/Chief_Executive_Officer +
, http://dbpedia.org/resource/Abdominoplasty +
, http://dbpedia.org/resource/Category:Biotechnology_companies_of_the_United_States +
, http://dbpedia.org/resource/NeuVax +
, http://dbpedia.org/resource/Dermatology +
, http://dbpedia.org/resource/Aventis +
, http://dbpedia.org/resource/Marlborough%2C_Massachusetts +
, http://dbpedia.org/resource/Food_and_Drug_Administration +
, http://dbpedia.org/resource/Biotechnology +
, http://dbpedia.org/resource/Macular_Degeneration +
, http://dbpedia.org/resource/Melanoma +
, http://dbpedia.org/resource/Middlesex_County%2C_Massachusetts +
|
| http://dbpedia.org/property/foundation
|
2011
|
| http://dbpedia.org/property/industry
|
http://dbpedia.org/resource/Biotechnology +
|
| http://dbpedia.org/property/keyPeople
|
Robert Bitterman
, Geert Cauwenbergh
|
| http://dbpedia.org/property/location
|
http://dbpedia.org/resource/Marlborough%2C_Massachusetts +
|
| http://dbpedia.org/property/name
|
Phio Pharmaceuticals
|
| http://dbpedia.org/property/tradedAs
|
NASDAQ:PHIO
|
| http://dbpedia.org/property/type
|
http://dbpedia.org/resource/Public_company +
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:URL +
, http://dbpedia.org/resource/Template:Third-party +
, http://dbpedia.org/resource/Template:Infobox_company +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Biotechnology_companies_of_the_United_States +
, http://dbpedia.org/resource/Category:Companies_listed_on_the_Nasdaq +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Phio_Pharmaceuticals?oldid=1082536316&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Phio_Pharmaceuticals +
|
| http://xmlns.com/foaf/0.1/name
|
Phio Pharmaceuticals
|
| owl:sameAs |
http://www.wikidata.org/entity/Q25245130 +
, https://global.dbpedia.org/id/2Nscp +
, http://dbpedia.org/resource/Phio_Pharmaceuticals +
|
| rdf:type |
http://www.wikidata.org/entity/Q24229398 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#Agent +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#SocialPerson +
, http://dbpedia.org/ontology/Company +
, http://schema.org/Organization +
, http://www.wikidata.org/entity/Q43229 +
, http://www.wikidata.org/entity/Q4830453 +
, http://dbpedia.org/ontology/Agent +
, http://dbpedia.org/ontology/Organisation +
|
| rdfs:comment |
Phio Pharmaceuticals Inc. is a US biotechn … Phio Pharmaceuticals Inc. is a US biotechnology company focused on the field of siRNA. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phios Pharmaceuticals in 2018. The company is using its siRNA platform to develop a pipeline of dermatology and ophthalmology therapeutics. The company has developed self-delivering RNAi compounds for the treatment of dermal and retinal scarring and is also working on a proprietary topical formulation of diphenylcyclopropenone for the treatment of warts, alopecia areata and cutaneous metastases of melanoma.eata and cutaneous metastases of melanoma.
|
| rdfs:label |
Phio Pharmaceuticals
|
